On the 8th of June, reporter Gordon Chree from STV visited Quotient's Allan-Robb Campus in Penicuik, Scotland to interview Quotient Chief Operating Officer. While on site, he was also tested using the MosaiQ COVID-19 Antibody Microarray.
On the 6th of June 2020, The Sun journalist Alex Bellotti visited an hVIVO laboratory in East London to try out the newly launched “gold standard” coronavirus antibody test provided by Quotient using their MosaiQ technology.
JERSEY, Channel Islands, May 11, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, and hVIVO, part of Open Orphan plc (LONDON:ORPH), today announced that the MosaiQ™ by Quotient system and MosaiQ
JERSEY, Channel Islands, 1 May, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced that it has completed the process for declaring conformity to the essential requirements of the In V
JERSEY, Channel Islands, April 27, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported very strong final study performance data for its SARS-CoV-2 antibody test.
JERSEY, Channel Islands, April 21, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported positive performance data for its SARS-CoV-2 antibody test.
Experts say antibody testing will play a crucial role in easing coronavirus lockdowns around the world and reviving economies.
Quotient warns global shortages of critical components could hamper efforts
To read the full article, visit: Financial Times
JERSEY, Channel Islands, April 06, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced the completion of the development phase of a microarray based SARS-CoV-2 (COVID-1